Aerie Pharmaceuticals (AERI) Receives ‘Analyst’ Rating

Aerie Pharmaceuticals (AERI) : The consensus on Aerie Pharmaceuticals (AERI) based on 5 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Aerie Pharmaceuticals (AERI) : 5 investment research analysts covering Aerie Pharmaceuticals (AERI) have an average price target of $45.4 for the near short term. The highest target price given by the Brokerage Firm to the stock is $50 and the lowest target is $40 for the short term. Analysts expect the variance to be within $3.85 of the average price.


Also, Cantor Fitzgerald initiates coverage on Aerie Pharmaceuticals (NASDAQ:AERI). Cantor Fitzgerald has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $44 per share. The rating by the firm was issued on June 2, 2016.

Aerie Pharmaceuticals (NASDAQ:AERI): After opening at $34.425, the stock dipped to an intraday low of $29.6 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $34.6863 and the buying power remained strong till the end. The stock closed at $30.61 for the day, a gain of 44.87% for the day session. The total traded volume was 16,133,498. The stocks close on the previous trading day was $21.13.

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.